| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jason S Knight | |
| W Joseph McCune | |||
| Paula L Bockenstedt | |||
| Andrew P Vreede | |||
| P2860 | cites work | {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome | Q28115185 |
| Correction of thrombocytopenia with aspirin in the primary antiphospholipid syndrome | Q28191926 | ||
| The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women | Q28213032 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia | Q28305486 | ||
| Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura | Q33268017 | ||
| Plasma exchange for thrombocytopenia in antiphospholipid syndrome: a case report | Q33328650 | ||
| Clinical study and follow-up of 100 patients with the antiphospholipid syndrome | Q33331100 | ||
| Splenectomy for refractory Evans' syndrome associated with antiphospholipid antibodies: report of two cases. | Q33334858 | ||
| Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study | Q33338827 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome | Q33363176 | ||
| Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? | Q33367182 | ||
| The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome | Q33369426 | ||
| High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia | Q33374739 | ||
| Primary antiphospholipid syndrome with thrombotic thrombocytopenic purpura: a very unusual association | Q33385254 | ||
| Use of rituximab in the antiphospholipid syndrome | Q33389337 | ||
| A novel mechanism of thrombosis in antiphospholipid antibody syndrome. | Q33390825 | ||
| Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations | Q33394044 | ||
| Thrombopoietin-receptor agonists in haematological disorders: the Danish experience | Q33398815 | ||
| A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome | Q33404206 | ||
| Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus | Q33404430 | ||
| Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim | Q33406819 | ||
| Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome | Q33414595 | ||
| Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag | Q33414666 | ||
| Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus | Q33418800 | ||
| Catastrophic APS in the context of other thrombotic microangiopathies | Q33419886 | ||
| The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features | Q33420116 | ||
| The significance and management of thrombocytopenia in antiphospholipid syndrome | Q33420910 | ||
| Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators. | Q33422067 | ||
| Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist | Q33425552 | ||
| Is ITP a thrombophilic disorder? | Q33427394 | ||
| Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies | Q33431551 | ||
| A rare combination of thrombotic thrombocytopenic purpura and antiphospholipid syndrome | Q33437178 | ||
| Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria. | Q33438938 | ||
| Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study | Q33439387 | ||
| Use of eltrombopag for secondary immune thrombocytopenia in clinical practice | Q33442354 | ||
| Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study | Q33443108 | ||
| Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia | Q33491169 | ||
| Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura | Q33491459 | ||
| Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. | Q33492107 | ||
| Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome. | Q33495873 | ||
| Reversal of thrombocytopenia following oral anticoagulation in two patients with primary antiphospholipid syndrome | Q33496560 | ||
| Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome | Q33499651 | ||
| Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia | Q33500103 | ||
| Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome | Q33500479 | ||
| Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases | Q33500886 | ||
| Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy | Q33503507 | ||
| Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. | Q33948737 | ||
| The challenges of lupus anticoagulants | Q38703934 | ||
| Treatment of catastrophic antiphospholipid syndrome | Q38755260 | ||
| In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis | Q39328138 | ||
| Neutrophil activation by anti-beta 2 glycoprotein I monoclonal antibodies via Fc gamma receptor II. | Q41362641 | ||
| Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. | Q41818166 | ||
| Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target | Q42162703 | ||
| Thrombocytopenia in high-risk patients with antiphospholipid syndrome | Q50112309 | ||
| Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management | Q50209337 | ||
| 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. | Q51289629 | ||
| Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two Phase 3, Randomized, Placebo-Controlled Trials. | Q52562217 | ||
| Is There an Association Between Heparin-Induced Thrombocytopenia (HIT) and Autoimmune Disease? | Q52574317 | ||
| Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series. | Q53072831 | ||
| Anti-β2 glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2' and glycoprotein I bα. | Q53399550 | ||
| Adverse Effects of Immunoglobulin Therapy. | Q55465940 | ||
| Thrombotic Microangiopathies with Rheumatologic Involvement | Q57025047 | ||
| Management of antiphospholipid syndrome | Q57033429 | ||
| Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study | Q57785626 | ||
| Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study | Q58119067 | ||
| Neutrophil accumulation and NET release contribute to thrombosis in HIT | Q59125543 | ||
| Distinct antibody profile: a clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus? | Q61974452 | ||
| Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome | Q64045589 | ||
| Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus | Q68153286 | ||
| Syndrome of the black swan | Q69418368 | ||
| Dapsone in thrombocytopenia of the antiphospholipid antibody syndrome | Q72157708 | ||
| Thrombocytopenia in the antiphospholipid syndrome | Q73306638 | ||
| The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction | Q80874460 | ||
| Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus | Q85233702 | ||
| Thrombopoietin-receptor agonist as a treatment of thrombocytopenia associated with systemic lupus erythematosus | Q85257178 | ||
| Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events | Q86259030 | ||
| Letter to the editor. Commentary to the article: LaMoreaux B, Barbar-smiley F, Ardoin S, Madhoun H. Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostin, a thrombopoietin r | Q86743615 | ||
| Thrombotic risk of reduced ADAMTS13 activity in patients with antiphospholipid antibodies | Q87059317 | ||
| Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome | Q87063468 | ||
| Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort | Q88153708 | ||
| The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository | Q88399624 | ||
| Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists | Q88661765 | ||
| The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review | Q88741390 | ||
| Effects of anti-β2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity | Q90480644 | ||
| Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature | Q90627745 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatology | Q327657 |
| antiphospholipid antibodies | Q582142 | ||
| antiphospholipid syndrome | Q582207 | ||
| thrombocytopenia | Q585285 | ||
| P304 | page(s) | 231-240 | |
| P577 | publication date | 2019-05-01 | |
| P1433 | published in | Current Opinion in Rheumatology | Q15750473 |
| P1476 | title | Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome | |
| P478 | volume | 31 |
Search more.